{
      "StudyFieldsResponse": {
            "APIVrs": "1.01.05",
            "DataVrs": "2022:10:12 23:20:22.323",
            "Expression": "mesenchymal allo-APZ2-EB",
            "NStudiesAvail": 430639,
            "NStudiesFound": 2,
            "MinRank": 1,
            "MaxRank": 1000,
            "NStudiesReturned": 2,
            "FieldList": [
                  "MaximumAge",
                  "MinimumAge",
                  "NCTId",
                  "NCTIdAlias",
                  "OfficialTitle",
                  "OrgClass",
                  "OrgFullName",
                  "OrgStudyId",
                  "OrgStudyIdDomain",
                  "OrgStudyIdLink",
                  "OrgStudyIdType",
                  "OtherEventAssessmentType",
                  "OtherEventNotes",
                  "OtherEventOrganSystem",
                  "OtherEventSourceVocabulary"
            ],
            "StudyFields": [
                  {
                        "Rank": 1,
                        "MaximumAge": [
                              "55 Years"
                        ],
                        "MinimumAge": [
                              "0 Years"
                        ],
                        "NCTId": [
                              "NCT03529877"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "An Interventional, Multicenter, Single Arm, Phase I/IIa Clinical Trial to Investigate the Efficacy and Safety of Allo-APZ2-EB on Epidermolysis Bullosa (EB)"
                        ],
                        "OrgClass": [
                              "INDUSTRY"
                        ],
                        "OrgFullName": [
                              "RHEACELL GmbH & Co. KG"
                        ],
                        "OrgStudyId": [
                              "allo-APZ2-EB-II-01"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 2,
                        "MaximumAge": [],
                        "MinimumAge": [],
                        "NCTId": [
                              "NCT05464381"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "A Double-blind, Randomized, Placebo-controlled, Interventional, Multicenter, Phase III Clinical Trial to Investigate the Safety and Efficacy of ABCB5-positive Mesenchymal Stromal Cells (ABCB5+ MSCs) on Epidermolysis Bullosa (EB)"
                        ],
                        "OrgClass": [
                              "INDUSTRY"
                        ],
                        "OrgFullName": [
                              "RHEACELL GmbH & Co. KG"
                        ],
                        "OrgStudyId": [
                              "allo-APZ2-EB-III"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  }
            ]
      }
}